3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 7 areas
0
News (30d)
Quiet
SN BioScience Inc. is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cardia cancer | 7-ethtyl-10-hydroxycamptothecin and irinotecan | Des.TrialAppr. |
| gastric cancer | 7-ethtyl-10-hydroxycamptothecin and irinotecan | Des.TrialAppr. |
| malignant pancreatic neoplasm | combination of 7-ethtyl-10-hydroxycamptothecin and irinotecan hydrochloride trihydrate | Des.TrialAppr. |
| pylorus cancer | 7-ethtyl-10-hydroxycamptothecin and irinotecan | Des.TrialAppr. |
| small cell lung carcinoma | 7-ethyl-10-hydroxycamptothecin and irinotecan hydrochloride trihydrate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
41
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
41
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio